101 Therapeutics has developed the first-ever targeted glucocorticoid with all of the potency of steroids and none of the systemic toxicities. By targeting the host immune system rather than the pathogen itself, the company can effectively treat a multitude of infectious diseases, whether viral, parasitic, or bacterial.
Classification
Sector
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Core Technology
BiologicalsMolecules
Target Customer
Healthcare & Life SciencesLife SciencesPharmaceuticals